share_log

Akanda Announces No Equity Financing Until Further Notice

Akanda Announces No Equity Financing Until Further Notice

阿坎達宣佈在另行通知之前不進行股權融資
newsfile ·  04/15 21:30

London, United Kingdom--(Newsfile Corp. - April 15, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, previously announced the completion of several public offerings and the sale of its indirectly wholly-owned Portuguese subsidiary, RPK BioPharma Unipessoal, LDA ("RPK") now announces its plans to pause any potential equity financings for a thirty (30) day period while the Board meets and confers. The Company plans to evaluate and pursue strategic investments in international cannabis plant touching markets as well as ancillary technology services.

英國倫敦--(Newsfile Corp.,2024年4月15日)——國際醫用大麻公司阿坎達公司(納斯達克股票代碼:AKAN)(“阿坎達” 或 “公司”)此前宣佈已完成幾次公開募股,並出售其間接全資擁有的葡萄牙子公司RPK Biopharma Unipessoal, LDA(“RPK”)現在宣佈計劃將任何潛在的股權融資暫停三十年(30) 董事會開會和授權。該公司計劃評估並對涉及市場的國際大麻植物以及輔助技術服務進行戰略投資。

Since February 1, 2024, the Company completed shelf offerings in the aggregate gross amount of $983,000 and a firm commitment underwritten public offering in the aggregate gross amount of $5,000,000, each before deducting discounts, commission and offering expenses and fees. Furthermore with the sale of RPK, Akanda eliminated approximately $4M of debt and received net cash proceeds of $1,553,750. Interim CEO and Director Katie Field commented, "We have been working around the clock this year to position Akanda to evaluate strategic opportunities and now the time has come ."

自2024年2月1日起,公司完成了總額爲98.3萬美元的貨架發行,並完成了總額爲500萬美元的堅定承諾公開發行,每次都扣除折扣、佣金和發行費用及費用。此外,通過出售RPK,阿坎達取消了約400萬美元的債務,並獲得了1,553,750美元的淨現金收益。臨時首席執行官兼董事凱蒂·菲爾德評論說:“我們今年一直在夜以繼日地工作,讓阿坎達評估戰略機會,現在時機已經到來。”

The Company plans to review possible acquisitions in international cannabis and technology sectors and evaluate each opportunity based on current operations and potential for future growth. Ms. Field continued, "We have amassed a stronger cash position but do not intend to invest in future subsidiaries that increase Akanda's burn rate. We plan to be thoughtful about future additions to the Company."

該公司計劃審查國際大麻和技術領域可能的收購,並根據當前的業務和未來增長潛力對每個機會進行評估。菲爾德女士繼續說:“我們已經積累了更強勁的現金狀況,但不打算投資未來會提高Akanda銷燬率的子公司。我們計劃考慮公司未來的增員。”

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Company's securities, nor shall there be any sale of such securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

本新聞稿不構成出售要約或徵求購買公司證券的要約,在根據任何此類州或其他司法管轄區的證券法進行註冊或獲得資格認證之前,在任何州或其他司法管轄區出售此類證券是非法的,也不得在任何州或其他司法管轄區出售此類證券。任何證券的要約、邀約或要約或任何證券銷售都將根據經修訂的1933年《證券法》的註冊要求提出。

About Akanda Corp.

關於阿坎達公司

Akanda is an international medical cannabis and wellness platform company seeking to help people lead better lives through improved access to high quality and affordable products. Akanda's portfolio includes CanMart, a UK-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the UK. The Company's seed-to-patient supply chain also includes partnerships Cellen Life Sciences' Leva Clinic, one of the first fully digital pain clinics in the UK. Akanda also acquired the right to develop a Canadian farming property in British Columbia, including farming land and related operations and licenses. The Company plans to develop THC and cannabinoid (CBD) facilities at this site.

Akanda是一家國際醫用大麻和健康平台公司,旨在通過改善獲得高質量和負擔得起的產品的機會,幫助人們過上更好的生活。阿坎達的投資組合包括CanMart,這是一家總部位於英國的全牌藥品進口商和分銷商,爲英國境內的藥房和診所提供服務。該公司的從種子到患者的供應鏈還包括合作伙伴Cellen Life Sciences的Leva Clinic,這是英國首批完全數字化的疼痛診所之一。阿坎達還獲得了在不列顛哥倫比亞省開發加拿大農業地產的權利,包括耕地和相關運營和許可證。該公司計劃在該地點開發四氫大麻酚和大麻素(CBD)設施。

Connect with Akanda: Email | Website | LinkedIn | Twitter | Instagram

聯繫 Akanda:電子郵件 | 網站 | LinkedIn | Twitter | Instagram

Investor Contact

投資者聯繫人

ir@akandacorp.com

ir@akandacorp.com

Cautionary Note Regarding Forward-Looking Information and Statements

關於前瞻性信息和陳述的警示說明

This press release contains certain "forward-looking information" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only Akanda's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Akanda's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved" and similar expressions and include statements regarding the timing and completion of the proposed offering. Forward-looking information may relate to anticipated events or results including, but not limited to business strategy, product development and sales and growth plans. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Akanda does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

本新聞稿包含1995年《美國私人證券訴訟改革法》安全港條款所指的某些 “前瞻性信息”。此類前瞻性信息和前瞻性陳述不能代表歷史事實或信息或當前狀況,而僅代表阿坎達對未來事件、計劃或目標的信念,其中許多事情、計劃或目標本質上是不確定的,不在阿坎達的控制範圍內。通常,此類前瞻性信息或前瞻性陳述可以通過使用前瞻性術語來識別,例如 “計劃”、“預期” 或 “不預期”、“預算”、“預期”、“估計”、“打算”、“預期” 或 “不相信”,或此類詞語和短語的變體或可能包含某些行爲、事件或結果 “可能” 的陳述、“可以”、“將”、“可能” 或 “將被採取”、“將繼續”、“將發生” 或 “將實現” 以及類似的表述幷包括聲明關於擬議發行的時間和完成情況。前瞻性信息可能與預期事件或結果有關,包括但不限於業務戰略、產品開發以及銷售和增長計劃。本新聞稿中包含的前瞻性信息和前瞻性陳述自本新聞稿發佈之日起作出,除非根據適用的證券法,否則阿坎達不承諾更新此處包含或引用的任何前瞻性信息和/或前瞻性陳述。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論